Clinical significance of serum
            <scp>YKL</scp>
            ‐40 in Behçet disease

Seo, Ja Yeong; Ahn, Young Soo; Zheng, Zhenlong; Kim, B O; Choi, Moon; Bang, Dongsik; Kim, D Y

doi:10.1111/bjd.14376

Cited by 12 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chitinase3-like1 has recently received considerable attention as marker for inflammation in BD patients ( 33 , 34 ). Indeed a Korean study on 112 patients with BD whose main clinical features were recurrent oral ulcers and skin lesions, has shown increased serum levels of Chitinase3-like1 and a positive correlation with disease activity ( 17 ). These results are in agreement with Bilen et al that showed higher serum levels of Chitinase3-like1 in BD patients compared with HC, albeit they did not correlate with disease activity ( 35 ).…”

Section: Discussionmentioning

confidence: 99%

“…Indeed, molecules such as Chitinase3-like1 regulating monocytes differentiation, as well as antibacterial and type 17 responses, was observed to be upregulated in BD patients compared to healthy control (HC). Interestingly, this cytokine was also seen to be associated to disease activity in BD, correlating positively with elevated IL-6 serum levels ( 17 – 19 ).…”

Section: Introductionmentioning

confidence: 93%

See 1 more Smart Citation

Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease

et al. 2017

View full text Add to dashboard Cite

Behçet’s disease (BD) is a multi-systemic inflammatory disorder consisting of recurrent oral aphthosis, genital ulcers, and chronic relapsing bilateral uveitis; however, many other organs may be affected. Several pro-inflammatory cytokines, mainly derived from Th1 and Th17 lymphocytes, seem to be involved in different pathogenic pathways leading to development of the clinical manifestations. On this basis, the primary aim of our study was to compare a core set of pro-inflammatory cytokines between patients with BD and healthy control (HC). The secondary goal was to evaluate potential correlations between these putative circulating biomarkers, the status of disease activity, and the specific organ involvement at the time of sample collection. Fifty-four serum samples were collected from 46 BD patients (17 males, 29 females, mean age 45.5 ± 11.3 years), and 19 HC (10 males, 9 females, mean age 43 ± 8.3 years). Twenty-five serum cytokines (APRIL/TNFS13, BAFF/TNFSF13B, sCD30/TNFRSF8, sCD163, Chitinase3-like1, gp130/sIL-6Rb, IFNb, sIL-6Ra, IL-10, IL-11, IL-19, IL-20, IL-26, IL-27 (p28), IL-28A/IFN-lambda2, IL-29/IFN-lambda1, IL-32, IL-34, IL-35, LIGHT/TNFSF-14, Pentraxin-3, sTNF-R1, sTNF-R2, TSLP, and TWEAK/TNFSF-12) were simultaneously quantified using a Bio-Rad cytokine bead arrays. Serum concentration of sTNF-R1 (p < 0.01) and sTNF-R2 (p < 0.01) resulted higher in both active and inactive BD than HC, while Chitinase3-like1 (p < 0.05) and gp130/sIL-6Rb (p < 0.01) serum levels were significantly higher in inactive BD, and IL-26 (p < 0.01) in active BD than HC. No differences were observed between inactive and active BD group. In addition, we observed that gp130/sIL-6Rb, sIL-6Ra, IL-35, and TSLP serum levels were significantly enhanced in patients with mucocutaneous manifestations plus ocular involvement (MO-BD) compared to subgroup with only mucocutaneous involvement (M-BD). Our findings may suggest a signature of IL-6, tumor necrosis factor-α as well as of Th17 response in BD patients due to increased levels of gp130/sIL-6Rb, sTNF-R1, sTNF-R2, IL-26, respectively. This evidence could contribute to improve the knowledge regarding the role of these citokines in the induction of specific BD clinical features.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 93%

Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Several point-based evaluating forms have been introduced to assess the activity of BS (12)(13)(14). Some scales are based purely on BS symptoms per se, while others also include laboratory examination results.…”

Section: Preoperative Preparations Examinations and The Best Time For Surgerymentioning

confidence: 99%

“…Observative indices that revile the activity of BS include oral and genetic ulcers, ocular symptoms, skin lesions, joint pain/arthritis, vomiting/ abdominal pain, diarrhea with bloody stool, and elevation of ESR (>20 mm) and CRP (>8 mg/L). However, the disease severity should be assessed by experienced rheumatologists as specific cut-off values to define the stage of BS are not currently available (12,13). In Japan, the activity of BS is determined to be active if a patient presents two or more major evaluating criteria (12).…”

Section: Preoperative Preparations Examinations and The Best Time For Surgerymentioning

confidence: 99%

Case report: laparoscopic radical cystectomy on a patient with Behçet’s syndrome, our initial experience on perioperative safety

Xue¹,

Yang²,

Ji³

et al. 2022

Transl Androl Urol

View full text Add to dashboard Cite

Behçet's syndrome (BS) is a rare systemic vasculitis that involves multiple systems and organs.Owing to the long-term prescription of immunosuppressive drugs, patients with BS are prone to urothelial tumors. However, surgical treatment in these cases could be dangerous because of the potential BS-related vasculitis, bleeding, and anastomotic necrosis. Literature reported that only five radical cystectomy cases had been performed on patients with BS, whereas the perioperative mortality was 40%. Moreover, perioperative managements on these cases were less discussed due to their multidisciplinary nature and rarity. We herein report a 54-year-old patient with a 13-year history of BS, diagnosed with sarcomatoid urothelial carcinoma and successfully underwent laparoscopic radical cystectomy with bilateral ureterocutaneostomy. No evidence of tumor residual or ureterocutaneostomic necrosis was reported in the subsequent three months of followup. In this case, the advantages of minimally invasive surgery in dealing with the parailiac lymph nodes were demonstrated. This article presented our thoughts, strategies, and experience on ensuring the patient's perioperative safety, as well as the selection of urinary diversion. We reviewed the literature in both English and Mandarin Chinese. Currently, two published articles describe the adoption of cystectomy in treating bladder cancer patients complicated with BS, whereas not any had shared the experience of using minimally invasive surgery. Hopefully, it could offer updated and enlightening significance to all related medical practitioners.

show abstract

“…Vascular endothelial growth factor (VEGF) levels have been observed in BD patients, particularly in active BD [229][230][231][232]. Several studies provided evidence for the increased levels of markers for endothelial activation or dysfunction such as vascular and intercellular adhesion molecules VCAM1, ICAM1, Selectins, and YKL40 in BD [233][234][235][236][237][238]. Various authors explored the association between certain genetic mutations and thrombosis in BD; however, results have been inconclusive [239][240][241][242][243][244], and current data indicate that the pathogenesis of thrombosis in BD is not due to a coagulation abnormality [245].…”

Section: Other Possible Markersmentioning

confidence: 99%

Etiology, Immunopathogenesis and Biomarkers in Behçet’s disease

Adeeb¹,

Khan²,

Stack³

et al. 2017

Behcet's Disease

View full text Add to dashboard Cite

Behçet's disease (BD) is a type of vasculitis with many distinctive clinical manifestations and multifactorial immunopathogenesis. The cause of BD remains unknown, but it has been postulated that in a genetically predisposed or susceptible population, exogenous agents trigger the dysregulation of both autoinflammatory and autoimmune responses resulting in multisystem vasculitis. There are robust ongoing efforts across the globe to elucidate and identify signature markers to improve and assist in rapid diagnosis of the disease and to tailor the best therapy accordingly. While association of human leukocyte antigen (HLA)-B * 51 (B * 51:01 subtype) allele is well recognized as the strongest genetic susceptibility gene so far among genetically predisposed BD patients, further investigations using the latest technology have led to the identification of several novel single nucleotide polymorphisms (SNPs) and other associated genes involved in the pathogenesis. There are several "established" cytokines known to be involved in the pathogenesis of BD, which have been further implicated in the genome-wide association studies (GWAS)-based cytokine/receptor gene loci studies, as well as numerous "novel" cytokines, which are currently being studied and identified. This chapter offers insights into current knowledge and thoughts regarding the future of biomarkers in BD.

show abstract

Clinical significance of serum YKL ‐40 in Behçet disease

Abstract: YKL-40 may play a role in the pathophysiology of BD and provide a useful marker for monitoring patients with BD.

Cited by 12 publications

References 32 publications

Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease

Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease

Case report: laparoscopic radical cystectomy on a patient with Behçet’s syndrome, our initial experience on perioperative safety

Etiology, Immunopathogenesis and Biomarkers in Behçet’s disease

Contact Info

Product

Resources

About